We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+55.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7B
AUM Growth
+$1.73B
(+33%)
Cap. Flow
-$5.41M
Cap. Flow
% of AUM
-0.08%
Top 10 Holdings %
Top 10 Hldgs %
37.61%
Holding
156
New
40
Increased
17
Reduced
34
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETNB
89bio
ETNB
|
+$111M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$97.4M |
| 3 |
Glaukos
GKOS
|
+$94.2M |
| 4 |
Danaher
DHR
|
+$91.1M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$77.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVDR
Avedro, Inc Common Stock
AVDR
|
+$96.3M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
+$79.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$66.9M |
| 4 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$55.9M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$45.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.81% |
| 2 | Financials | 1.53% |
| 3 | Miscellaneous | 0.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
AtriCure
ATRC
$2.86B
| $5.48M | 0.08% |
+168,621
| New | +$4.8M |
|
|
AMRN
102
Amarin Corp
AMRN
$294M
| $5.35M | 0.08% |
12,480
+1,425
| +13% | +$541K |
|
103
Personalis
PSNL
$1.72B
| $5.27M | 0.08% |
483,842
| – | – |
|
|
SYBX
104
DELISTED
Synlogic
SYBX
| $5.24M | 0.07% |
135,333
| – | – |
|
105
Incyte
INCY
$24.7B
| $5.2M | 0.07% |
+59,500
| New | +$5.08M |
|
|
ARNA
106
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $5M | 0.07% |
110,000
| – | – |
|
107
Acadia Pharmaceuticals
ACAD
$4.61B
| $4.11M | 0.06% |
96,143
| – | – |
|
108
Intellia Therapeutics
NTLA
$1.59B
| $3.85M | 0.05% |
262,100
-65,500
| -20% | -$911K |
|
|
DERM
109
CALL
DELISTED
Dermira, Inc.
DERM
| $3.79M | 0.05% |
+250,000
| New | +$2.16M |
|
110
AstraZeneca
AZN
$251B
| $3.47M | 0.05% |
+34,800
| New | +$3.28M |
|
111
Sanofi
SNY
$102B
| $3.43M | 0.05% |
+68,400
| New | +$3.2M |
|
|
WHWK
112
Whitehawk Therapeutics
WHWK
$233M
| $3.24M | 0.05% |
346,263
| – | – |
|
113
BioMarin Pharmaceuticals
BMRN
$12.5B
| $2.93M | 0.04% |
+34,700
| New | +$2.62M |
|
|
KALV
114
DELISTED
KalVista Pharmaceuticals
KALV
| $2.86M | 0.04% |
160,541
+121,808
| +314% | +$1.59M |
|
|
ICPT
115
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.83M | 0.04% |
22,800
-9,400
| -29% | -$842K |
|
|
FLXN
116
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $2.75M | 0.04% |
+133,000
| New | +$2.24M |
|
117
Curis
CRIS
$2.74M
| $2.31M | 0.03% |
3,396
+292
| +9% | +$212K |
|
|
MYOK
118
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.03M | 0.03% |
27,900
-755,132
| -96% | -$45.8M |
|
119
Syndax Pharmaceuticals
SNDX
$1.62B
| $1.86M | 0.03% |
212,000
| – | – |
|
120
Eledon Pharmaceuticals
ELDN
$220M
| $1.85M | 0.03% |
176,851
| – | – |
|
121
Mirum Pharmaceuticals
MIRM
$6.1B
| $1.75M | 0.03% |
+71,300
| New | +$760K |
|
|
ADAP
122
DELISTED
Adaptimmune Therapeutics
ADAP
| $1.62M | 0.02% |
1,350,655
| – | – |
|
|
IMGN
123
DELISTED
Immunogen Inc
IMGN
| $1.46M | 0.02% |
+286,800
| New | +$973K |
|
124
Insmed
INSM
$26.2B
| $1.41M | 0.02% |
59,000
-503,300
| -90% | -$10.2M |
|
125
Protagonist Therapeutics
PTGX
$9.28B
| $1.35M | 0.02% |
+191,209
| New | +$1.9M |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q4 2019 Portfolio in Review
As of Q4 2019, OrbiMed held 156 positions worth $7B, up 33% from $5.27B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
OrbiMed's Q4 2019 filing shows 40 new, 17 increased, 34 reduced and 20 closed positions. Its largest new stake was 89bio: 4,004,442 shares worth $105M. The largest sale was Avedro, Inc Common Stock, an estimated $96.3M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.
- OrbiMed's largest Q4 2019 buy was 89bio: 4,004,442 shares worth $105M.
- OrbiMed added most to Mirati Therapeutics, Inc. Common Stock in Q4 2019, an estimated $77.7M increase.
- OrbiMed's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $66.9M.
- OrbiMed fully exited Avedro, Inc Common Stock in Q4 2019, selling an estimated $96.3M.
- OrbiMed's ten largest holdings make up 38% of its $7B portfolio in Q4 2019.
- OrbiMed opened 40 new positions and closed 20 in Q4 2019.
- OrbiMed's portfolio value rose 33% quarter-over-quarter to $7B.
Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.